Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2014.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics.
J Med Chem
November 2024
Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery, Hong Kong, Hong Kong SAR 999077, China.
Despite the extensive development of aptamers in basic research, only a limited number have successfully progressed to clinical trials. This limitation is primarily attributed to the inherent instability of aptamers' conformation, resulting in low affinity, poor serum stability, and inconsistent potency, posing a significant challenge to their stabilization. Herein, we established a feasible strategy to develop staple aptamers using the predicted binding conformations and titration cross-linking (TTC) method.
View Article and Find Full Text PDFMulti-omics analyses reveal aberrant differentiation trajectory with WNT1 loss-of-function in type XV osteogenesis imperfecta.
J Bone Miner Res
September 2024
Department of Orthopaedics and Traumatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China.
Osteogenesis imperfecta (OI) is a group of severe genetic bone disorders characterized by congenital low bone mass, deformity, and frequent fractures. Type XV OI is a moderate to severe form of skeletal dysplasia caused by WNT1 variants. In this cohort study from southern China, we summarized the clinical phenotypes of patients with WNT1 variants and found that the proportion of type XV patients was around 10.
View Article and Find Full Text PDFMultidisciplinary Management of Pregnancy in Patients With Osteogenesis Imperfecta Type 3.
Perm J
September 2024
Department of Maternal-Fetal Medicine, Kaiser Permanente, Santa Clara, CA, USA.
Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease.
Mol Med
May 2024
School of Medicine, China Medical University, Taichung City, 404328, Taiwan.
Article Synopsis
- The study investigates the use of Dickkopf-1 antisense (DKK1-AS) as a potential treatment for osteogenesis imperfecta (OI), addressing limitations in current treatments.
- Analysis of serum DKK1 levels showed significant correlations with bone density metrics in OI patients and found that DKK1-AS treatment improved various aspects of bone health in OI mice.
- Key findings indicate that DKK1-AS not only enhances bone density and structure but also positively influences osteogenic gene transcription and reduces harmful osteoclast activity in OI mice.
Correlation of serum DKK1 level with skeletal phenotype in children with osteogenesis imperfecta.
J Endocrinol Invest
November 2024
Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan No. 1, Beijing, 100730, Dongcheng District, China.
Purpose: We aim to detect serum DKK1 level of pediatric patients with OI and to analyze its relationship with the genotype and phenotype of OI patients.
Methods: A cohort of pediatric OI patients and age-matched healthy children were enrolled. Serum levels of DKK1 and bone turnover biomarkers were measured by enzyme-linked immunosorbent assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!